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mortality (1). As survival among patients with HF improves
and the incidence remains the same (2), the prevalence of
HF is increasing (3). Although patients with HF have
increased morbidity and mortality compared with disease-
free individuals, the causes for these are often noncardiac.
Indeed, noncardiovascular causes for hospital readmissions
after HF diagnosis are more common than cardiovascular
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, 2012; revised manuscript received March 20,attributed to noncardiovascular causes, particularly if the
ejection fraction (EF) is preserved (5). Although these data
are thought provoking, they typically reﬂect the evaluation of
comorbidity using composite indices (6), such that indi-
vidual comorbid conditions associated with HF are not well
delineated, the excess burden of a given comorbidity in HF
compared with HF-free subjects is not known, and the
impact on the outcome of a disease already characterized
by poor survival is unknown. These gaps in knowledge
underscore that noncardiac causes of morbidity in HF
warrant further investigation.
See page 887
Cancer is a major cause of morbidity in the population. A
total of 1,638,910 new cancer cases and 577,190 deaths from
cancer were projected to occur in the United States in 2012
(7). Yet the link between HF and cancer is not well char-
acterized. In particular, it is not known whether cancer is
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oping HF compared with that of
matched controls or whether HF
is associated with an excess risk
of cancer post-HF compared
with the risk for HF-free indi-
viduals. Further, the impact of
cancer on the outcome of HF is
not well delineated. These ques-tions are important because therapies for advanced HF are
expanding in use and there is a large patient and societal
burden associated with HF (8).
We hypothesized that there may be an increased risk of
cancer among HF patients. Therefore, the aims of our study
were to assess the association between cancer and risk of HF,
measure the excess risk of cancer among HF patients, and
determine the impact of cancer post-HF on survival in
a community population of optimal clinical relevance.Methods
Study setting. This study was conducted in Olmsted
County, Minnesota, under the auspices of the Rochester
Epidemiology Project. As previously described, Olmsted
County is isolated from other urban centers, and thus, only
a few providers deliver nearly all medical care to local resi-
dents (9). The medical records from these providers are
indexed through the Rochester Epidemiology Project,
resulting in the linkage of in- and outpatient records from all
sources of care used by the population, thereby providing
a unique infrastructure to analyze disease determinants and
outcomes (9).
Study design. This study was carried out in 2 stages. First,
a case-control study was performed with newly diagnosed
HF patients serving as cases and with subjects free of HF,
selected from the general population, serving as the controls.
Prior cancer history (veriﬁed by dates, classiﬁed by cancer
site) was the primary exposure of interest. Known risk factors
for HF or cancer were considered confounding factors.
Second, the HF patients and their matched controls were
followed to compare their long-term risk of incident cancer
using a cohort design. The study was approved by the
appropriate institutional review boards.
Selection of cases and controls. Case subjects were
Olmsted County residents with an incident diagnosis of HF
between 1979 and 2002. As previously described (2), HF
was deﬁned using the Framingham criteria (10).
Control subjects were selected from the same county
population. Controls were individually matched (1:1) to
cases on age (3 years), sex, and index date. The index date
for the control corresponds to the incidence date of the
matched HF case. Potential controls with HF before the
index date were excluded.
In any 3-year period, more than 90% of residents are seen at
the Mayo Clinic, and the majority are attended annually by
some local healthcare provider (9). Thus, the RochesterEpidemiology Project medical records linkage system
provides a virtually complete enumeration of the population
from which to sample controls. Obtaining information on
exposures before the index date from these community
medical records ensures similar opportunities for ascertain-
ment of risk factors in the 2 groups and avoids biases inherent
in many case-control studies (e.g., differential recall, nonre-
sponse bias, and survivor bias).
Follow-up. Cases and controls were subsequently followed
through the medical records. Follow-up began at the index
date and lasted until death or the most recent clinical
contact, whichever came ﬁrst (last follow-up, January 2012).
In the cohort, 92% of the HF cases and 89% of those
without HF (p ¼ 0.09) stayed in Olmsted County or within
a 30-mile radius, and thus continued to receive their care in
Olmsted County. As previously described, death was ascer-
tained using multiple sources (2).
Cancer data. Each subject’s complete medical history was
searched for the occurrence of any cancer through the
comprehensive diagnostic and surgical indices that are part
of the Rochester Epidemiology Project (9). Cancer types
were classiﬁed by anatomy and system of primary involve-
ment (11); nonmelanoma skin cancers were excluded from
the study. The date of ﬁrst cancer diagnosis was used as the
diagnosis date.
Clinical characteristics. Nurse abstractors collected clinical
data from the medical records at the time the cases and
controls were assembled. Myocardial infarction was ascer-
tained using a clinical diagnosis. The National Diabetes
Data Group criteria (12) were used to deﬁne diabetes.
Clinical deﬁnitions were used to assess hypertension and
dyslipidemia. Body mass index (BMI) (kg/m2) was calcu-
lated using the last weight before HF diagnosis and earliest
adult height. Smoking was dichotomized as current (at the
time of evaluation or within the previous 6 months) versus
not current. Comorbidity was summarized with the Charl-
son comorbidity index (6). EF was derived from echocar-
diography reports at the time of diagnosis of HF (90 days)
and dichotomized into “reduced” (<50%) or “preserved”
(50%).
Statistical analysis. For the case-control study, a matched
analysis was conducted. Baseline characteristics and prior
cancer were compared between cases and controls using
conditional logistic regression, with the matching identiﬁ-
cation number as the stratiﬁcation variable.
For the cohort study, the risk of developing incident cancer
in the HF patients during follow-up was directly compared
with their matched controls using a stratiﬁed proportional
hazards regression model with the strata being the case/
control pairs. Multivariable adjustment was made for sus-
pected risk factors for cancer. Stratiﬁed analyses by age, sex,
and index year were also performed. Differences in age, sex,
and index year were tested by individually including HF 
age, HF sex, andHF year interaction terms in the model.
Differences in the associations between HF and cancer
subtypes were tested and were not statistically signiﬁcant.
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between EF and incident cancer was assessed with a propor-
tional hazards regression model. The cumulative incidence of
cancer for up to 10 years following the index date was plotted,
with death as a competing event (13). Death as a competing
risk should be accounted for because the traditional Kaplan-
Meier method could substantially overestimate the cumula-
tive cancer incidence in the presence of strong competing
risks.
Finally, survival among HF cases and among controls was
assessed with the Kaplan-Meier method. The association
between cancer and death was evaluated using proportional
hazards modeling with cancer treated as a time-dependent
variable.
The proportional hazards assumption was tested for unad-
justed and adjusted models, and found to be valid. A pre-
speciﬁed p value of 0.05 was used as the cutoff for statistical
signiﬁcance except when testing interactions, when a pre-
speciﬁed p value of 0.10 was used. Analyses were performed
using SAS version 9.3 (SAS Institute, Cary, North Carolina)
and R version 2.14.0 (the R Foundation for Statistical
Computing, Vienna, Austria).Results
Clinical characteristics at index. The study included 961
patients with incident HF (age: 75.5  12.7 years; 54%
women) and 961 matched controls. Subject characteristics
by HF status are presented in Table 1. HF patients had
a higher frequency of prior myocardial infarction, as well as
traditional cardiovascular risk factors, including hyperten-
sion, diabetes, and smoking, but not hyperlipidemia. In
addition, they had higher mean BMIs and more comor-






Age, yrs 75  13 75  13
Female 517 (54) 517 (54)
Body mass index, kg/m2 26.9  6.4 25.4  6.5
Prior myocardial infarction 208 (22) 80 (8)
Hypertension 643 (67) 563 (59)
Hyperlipidemia 279 (29) 302 (31)
Diabetes mellitus 181 (19) 78 (8)
Current smoking 155 (16) 84 (9)
Peripheral vascular disease 199 (21) 121 (13)
Dementia 64 (7) 99 (10)
Chronic obstructive pulmonary disease 198 (21) 114 (12)
Renal dysfunction 33 (3) 18 (2)
Charlson comorbidity index
0 245 (25) 394 (41)
1–2 476 (50) 444 (46)
3 240 (25) 123 (13)
Values are mean  SD or n (%). Patient characteristics among Olmsted County, Minnesota, residen
and year-matched community controls and are stratiﬁed by study design.diagnosis, 209 (22%) HF patients and 219 (23%) controls
had a history of cancer recorded. No association existed
between cancer diagnosis and development of subsequent
HF (odds ratio [OR]: 0.94; 95% conﬁdence interval [CI]:
0.75 to 1.17).
HF and subsequent cancer risk. To investigate the inci-
dence of cancer among HF patients, we excluded case-
control pairs where either the case or control had a prior
cancer diagnosis, resulting in 596 pairs in the cohort anal-
ysis. Their characteristics (Table 1) were similar to the initial
case-control groups. During 9,203 person-years of follow-up
(follow-up: 7.7  6.4 years), 244 new cancer cases were
identiﬁed (102 among HF patients and 142 among
controls). The cumulative incidence of cancer among HF
patients and matched controls is shown in Figure 1. The
incidence of cancer between HF patients and the controls
was similar initially but diverged after 2 years of follow-up,
with higher rates among the HF patients. Of the 244
cancers, 48 were digestive system cancers, 46 male repro-
ductive, 39 hematologic, 24 breast, 20 respiratory, 19
urinary, 7 female reproductive, 7 skin, and 34 were other
cancers.
Patients with HF had a 60% higher risk of developing
incident cancer (hazard ratio [HR]: 1.60; 95% CI: 1.14
to 2.26) compared with the controls and accounting for
the matching variables. This remained unchanged after
further adjustment for BMI, smoking, and the Charlson
comorbidity index (HR: 1.68; 95% CI: 1.13 to 2.50). Add-
ing former smoking to the model did not change the
HR estimate (HR: 1.67; 95% CI: 1.12 to 2.50), and no
smokingHF status interaction was detected (p¼ 0.63). A
similar association between HF and cancer risk was found
after adjusting for BMI, smoking, diabetes, prior myocar-







0.98 73  14 73  14 0.54
1.00 317 (53) 317 (53) 1.00
<0.001 27.5  6.6 25.6  7.3 <0.001
<0.001 125 (21) 38 (6) <0.001
<0.001 401 (67) 322 (54) <0.001
0.21 174 (29) 177 (30) 0.83
<0.001 116 (20) 47 (8) <0.001
<0.001 109 (19) 54 (9) <0.001
<0.001 116 (20) 74 (12) 0.001
0.003 30 (5) 54 (9) 0.006
<0.001 111 (19) 63 (11) <0.001
0.04 15 (3) 11 (2) 0.42
<0.001 16 (27) 266 (45) <0.001
300 (50) 260 (44)
135 (23) 70 (12)
ts with incident heart failure (HF) diagnosed in 1979 to 2002 are compared with age-, sex-,
Figure 1 Incidence of Cancer Among HF Patients and Controls
Cumulative incidence of cancer among heart failure (HF) patients and matched
controls, with death considered a competing event.
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1.64; 95% CI: 1.07 to 2.51).
We further investigated the association of HF and inci-
dent cancer in subgroups. Comparing men and women,
there was no statistically signiﬁcant difference in the asso-
ciations (p for HF  sex interaction ¼ 0.74). Men with HFFigure 2 Incidence of Cancer Among HF Patients and Controls by Ye
Cumulative incidence of cancer among heart failure (HF) patients and matched controls,had a 55% increased risk of developing incident cancer
compared with men without HF (HR: 1.55; 95% CI: 0.85
to 2.80), whereas women with HF had a 71% greater risk
(HR: 1.71; 95% CI: 0.99 to 2.95) after adjustment for BMI,
smoking, and the Charlson comorbidity index. Regarding
age, there was no statistically signiﬁcant difference in the
associations (p for HF  age group interaction ¼ 0.22).
Subjects 75 years of age with HF had more than a 2-fold
increased risk in developing incident cancer than their HF-
free counterparts (HR: 2.06; 95% CI: 1.15 to 3.71), whereas
subjects >75 years of age had a 30% higher risk (HR: 1.29;
95% CI: 0.73 to 2.29).
In analyses restricted to HF patients, the association
between left ventricular function and incident cancer was
examined. The EF was recorded in 368 HF patients; 44%
had preserved EF. Among the patients with available EF
evaluation, 70 cancer cases were identiﬁed during follow-up.
Cancer was not associated with preserved versus reduced EF
(HR: 0.80; 95% CI: 0.49 to 1.31) after adjustment for age,
sex, and index year. Further adjustment for the Charlson
comorbidity index yielded similar results (HR: 0.78; 95%
CI: 0.48 to 1.29).
The competing risk-adjusted cumulative incidence rates of
cancer among HF patients and matched controls by time
period are shown in Figure 2, illustrating an increased cancer
risk associated with HF during the later time period. Indeed,
from the stratiﬁed proportional hazards regressionmodel, p for
HF  year interaction was 0.075. For HF patients diagnosed
between 1979 and 1990, there was a 48% increased risk of
incident cancer in HF patients compared with HF-free
patients (HR: 1.48; 95% CI: 0.79 to 2.78), whereas HFar Groups
with death considered a competing event, stratiﬁed by year groups.
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increased risk (HR: 1.86; 95% CI: 1.10 to 3.15) after adjust-
ment for BMI, smoking, and theCharlson comorbidity index.
To minimize the possibility of co-occurrence of HF and
cancer, we repeated the analysis examining the association of
HF and cancer while excluding the ﬁrst 5 years of follow-up
after HF diagnosis. The results from the stratiﬁed propor-
tional hazards regression models were similar to those ob-
tained for the entire follow-up period (HR: 1.77; 95% CI:
0.97 to 3.20 in the model accounting for the matching
variables, and HR: 1.63; 95% CI: 0.83 to 3.21 in the model
further adjusted for BMI, smoking, and the Charlson
comorbidity index).
Mortality. Mortality was high in the HF cases. The 5-year
survival estimate for HF cases was 53% (95% CI: 49% to
57%). Incident cancer was associated with a large excess risk
of death (HR: 1.68; 95% CI: 1.33 to 2.14). This association
persisted after adjustment for age, sex, index year, and
Charlson comorbidity index (HR: 1.56; 95% CI: 1.22 to
1.99). Among the non-HF controls, the 5-year survival
estimate was 77% (95% CI: 73% to 80%). Incident cancer
was associated with a large increased risk of death (HR: 2.55;
95% CI: 2.03 to 3.22), which persisted after adjustment
for age, sex, index year, and the Charlson comorbidity index
(HR: 1.93; 95% CI: 1.51 to 2.46). There was no difference
in the association between cancer and mortality for cases
versus controls (p for HF  cancer interaction ¼ 0.18).
Discussion
In this community population, we have shown that although
the prevalence of cancer in newly diagnosed HF patients is
similar to controls, the incidence of subsequent cancer
diagnosis is approximately 70% higher among patients with
HF. The risk of cancer after HF is increasing over time and
is associated with increased mortality.
Incident cancer in HF patients. Because the ﬁnding of an
increased risk of cancer in HF is novel, studies will be
needed to examine the mechanisms of this association. Our
ﬁndings could reﬂect detection bias related to the intensiﬁed
medical evaluation due to the diagnosis of HF (e.g., evalu-
ation for transplantation). This is unlikely because in the
present study, none of the HF patients with reduced EF
who were diagnosed with cancer had a transplant work-up.
Additionally, the timing of cancer diagnosis in our study
suggests that detection bias is unlikely to operate. In our
experience, most diagnostic evaluations and corresponding
costs (14) occur in the ﬁrst year after HF diagnosis, whereas
the present ﬁndings indicate increased incident cancer after
the second year. Furthermore, the association persisted after
excluding individuals who developed cancer within 5 years of
HF diagnosis. The increased risk of cancer may relate to
shared risk factors between HF and cancer. For example,
patients with chronic obstructive pulmonary disease have an
increased risk for both HF and lung cancer (15), and chronic
kidney disease is associated with HF and an increased risk ofcancer in elderly men (16). This seems unlikely in the
present study, however, because adjustment for comorbid-
ities yielded similar results, and renal dysfunction was rare
and not signiﬁcantly different between cases and controls.
Further, the risk of cancer tended to be greater in younger
patients, arguing against a major role of measured and
unmeasured comorbidities, because these increase in preva-
lence with age. Other hypothetical explanations include the
possibility that stress from chronic illness (17) or mecha-
nisms associated directly with the physiology of HF may also
be operating in cancer, such as inﬂammation, tissue hypoxia,
and hormonal (erythropoietin) activation (18). None of
these are currently established.
Radiation from medical imaging is a concern (19,20);
however, the risks associated with radiation exposure are
typically long term, with cancer developing after 10 to
15 years, which is longer than the average survival after HF
diagnosis. Some cardiovascular medications may contribute
to the occurrence of malignancy (21). Calcium channel
blockers (11) and digoxin (22) seem unlikely culprits as none
of these agents occupies a central role in the treatment of
HF, and their use has declined over time, whereas the risk of
cancer has been increasing (23,24). Angiotensin-converting
enzyme inhibitors and angiotensin-receptor blockers stim-
ulate angiogenesis and thus, in theory, may increase cancer
risk (25). Their use has increased over time, and we observed
that the increased risk of cancer associated with HF tended
to be stronger in the later time period (1991 to 2002).
Although these parallel trends are concerning, they should
be viewed as hypothesis generating rather than reﬂecting
causality. Furthermore, alternative mechanisms, such as in-
creased risk of frailty in the context of improved survival,
should be investigated in future studies.
Mortality. Cancer was independently associated with an
increased risk of death in this cohort, as well as in previously
reported population registries (26). This is important
because the clinical implications of a cancer diagnosis in
a patient already diagnosed with HF are not fully deﬁned,
and it may be argued that outcomes will be determined by
HF. Our analysis does not support the latter view because
patients with HF who were later diagnosed with cancer had
a 56% higher risk of death compared with HF patients who
did not develop cancer. This information is relevant to
clinical decision making in HF.
Limitations, strengths, and clinical implications. Some
limitations of our study should be acknowledged. Data on
healthcare utilization were not available, so detection bias
cannot be ruled out. Our sample size did not afford analysis
of speciﬁc cancer types or cause-speciﬁc death. Estimation of
left ventricular function was not available in all patients, and
the analysis of the association between EF and incident
cancer should be interpreted with caution. No medication
data were available for controls and thus could not be
included in the analysis. Lastly, as is applicable to any
observational study, the observed associations could reﬂect
residual confounding, where the effect of a confounder is not
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ﬁndings should be interpreted as reﬂecting an association
rather than causality.
Our study also has notable strengths. We utilized the
comprehensive data resources of the Rochester Epidemi-
ology Project to examine cancer diagnoses occurring before
and after HF. We assembled a population-based incident
HF cohort with diagnosis conﬁrmed by standardized criteria
(2). The controls were randomly selected from the Olmsted
County population, and thus should be representative of the
community (9). Furthermore, clinical characteristics were
recorded before knowledge of cancer outcomes, and longi-
tudinal follow-up allowed the gain of novel insights into
clinical outcomes in HF.
Clinical implications. The increased incidence of cancer
among HF patients who already have an excess mortality
underscores the importance of cancer surveillance in this
population. The emergence of a greater risk in more recent
years will require particular watchfulness. These ﬁndings also
illustrate the importance of multimorbidity among patients
living with chronic diseases and support the concept of
providing holistic rather than disease-based care (27).
Conclusions
This community study indicates that patients with HF
experience a large excess risk of subsequent malignancies.
This excess risk appears to increase over time. Cancer
markedly increases mortality in HF, underscoring the
importance of noncardiac morbidity and of cancer surveil-
lance in the management of HF patients.
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